Breast Cancer Single-domain Antibody Development

Single-domain antibodies, also known as single-domain antibodies, represent a novel and promising therapeutic approach in the treatment of breast cancer. Derived from camelid antibodies, these unique immunoglobulins consist of only a single variable domain, which provides several advantages over traditional antibodies. At Alfa Cytology, we specialize in the development of single-domain antibodies tailored for breast cancer applications.

Introduction to Single-domain Antibody

Single domain antibodies, are proteins found naturally in camelids that are the smallest functional fragment of a heavy chain antibody that lacks the light chain and heavy chain CH1 constant regions. single-domain antibody is one-tenth the size of traditional antibodies while maintaining strong antigen recognition capabilities. It can be used in molecular imaging, tumor diagnosis, imaging-guided surgery, cancer treatment, etc.

single-domain antibody is also widely used in the field of breast cancer (BC) research. single-domain antibody-based molecular imaging can achieve precise staging and tumor heterogeneity evaluation of TNBC. single-domain antibody directed against antigens expressed by TNBC (TNF-α, EGFR, CD3, CTLA-4, STAT3, AKT2, etc.) can be used to detect, target, or sense cancer cells.

Fig.1 single-domain antibody production procedure. Fig.1 single-domain antibody production procedure. (Bakherad H, et al., 2022)

Single-domain Antibody Development for Breast Cancer

Breast cancer is a heterogeneous disease with various subtypes, each presenting distinct therapeutic challenges. Single domain antibodies can be engineered to target specific cancer antigens, such as HER2 or other tumor-associated markers, providing a targeted approach that can improve treatment efficacy while minimizing off-target effects. Their ability to modulate immune responses further enhances their potential as therapeutic agents, making them promising candidates in the evolving landscape of breast cancer therapies.

Target	Therapeutics	NCT	Phase
HER-2	68GaNOTA-Anti-HER2 VHH1	NCT03924466
PD-L1	KN035+ Trastuzumab/Docetaxel	NCT04034823

Our Services

Alfa Cytology provides single-domain antibody development services. single-domain antibody has advantages such as small size, easy production, low cost, and high stability, which make them attractive tools as cancer therapeutics or diagnostic agents.We can provide a variety of camel-derived single-domain antibody development services, including alpaca, llama, llama, llama, etc. Based on the phage display technology platform, Alfa Cytology can provide major experimental links including antigen design, alpaca immunization, library construction and screening, active function verification, etc., and provide scientists around the world with high-specificity and high-affinity single-domain antibody.

Step	Services
Alpaca immunity	A healthy adult alpaca (28-36 months) is vaccinated 5-7 times ELISA titer determination Antiserum collection
cDNA preparation (customers can provide cells)	Total RNA extraction High-fidelity RT-PCR preparation of cDNA
single-domain antibody library construction	Primer design and synthesis Using cDNA as a template, PCR amplifies the variable region of the heavy chain antibody gene Phagemid construction and transformation: enzyme digestion, ligation to phagemid vector, electroporation of TG1 host bacteria, and construction of antibody library Identification: randomly select 20-50 clones, PCR identification, sequencing, and analysis of antibody sequences
single-domain antibody library screening	Antigen extreme pressure method for 3 rounds of screening Identification: 96 clones were randomly selected and titer determined by ELISA Express 10-15 positive clones to prepare single-domain antibody supernatant

Advantages of Single-domain Antibody

Small Size and High Stability
Enhanced Binding Affinity
Ease of Engineering and Modification
Rapid Production and Scalability

Reduced Immunogenicity
Ability to Access Challenging Targets
Potential for Dual Targeting
Versatility in Applications

Alfa Cytology is a world-leading preclinical CRO company dedicated to assisting scientists around the world in BC research. We can provide you with BC-related single-domain antibody development services and help in the treatment and diagnosis of BC. If you have any questions about BC research, please contact us and our experts will get back to you as soon as possible.

Reference

Bakherad H, et al. Single-domain antibodies; new molecular instruments with special specifications for targeting, diagnosis and treatment of triple-negative breast cancer. Cancer Cell Int. 2022 Aug 6;22(1):245.

All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.